Wang and his colleagues were interested in improving PROTAC's ability to degrade target proteins inside cells. Drawing from their years of expertise in the fields of organic chemistry and chemical ...

Inside your body, countless processes are happening every second to keep you alive. Among them is a little-known but powerful ...

Alfa Chemistry now has an extensive range of products within the pharmaceutical field, including PROTAC building blocks, nucleosides, intermediates and Active Pharmaceutical Ingredients (APIs).

One such example is using artificial intelligence technology and novel approaches in targeted protein degradation, which has the potential to transform the way medicinal chemistry and drug discovery ...

The PROTAC candidates “… demonstrate potent ... “Now we have to keep going with medicinal chemistry optimization and see how well it works against the HIV reservoir in an animal model.” ...

The Phase I single ascending dose (SAD) and multiple ascending dose (MAD) trial (EUCT-2023-507910-28-00) found ARV-102, a proteolysis targeting chimaera (PROTAC) therapy, led to a drop in leucine ...

A PROTAC is a heterobifunctional molecule that can bind both a target protein and an E3 ubiquitin ligase to facilitate the formation of a ternary ... Through comparing how different warhead chemistry, ...

Pharmaceutical development of PROTAC (Proteolysis Targeting Chimera) molecules presents significant challenges due to their complex molecular structures, leading to low yields, ... we leverage our ...

Alfa Chemistry’s library includes many different PROTAC scaffolds needed to make these advanced bi-functional molecules. These include E3 ligase ligands such as CRBN and VHL, and linkers which act as ...